Lipplaa, Astrid
Fernandes, Ricardo
Marshall, Andrea
Lorigan, Paul
Dunn, Janet
Myers, Kevin A.
Barker, Emily
Newton-Bishop, Julia
Middleton, Mark R.
Corrie, Pippa G.
Article History
Received: 30 November 2017
Revised: 14 June 2018
Accepted: 20 June 2018
First Online: 23 July 2018
Ethics approval and consent to participate
: Regulatory approval and ethics approval from a multicentre ethics committee NRES Committee South Central—Oxford C were obtained (07/Q1606/15) and all patients gave written informed consent. The study was performed in accordance with the Declaration of Helsinki.
: Cancer Research UK C7535/A6408 (AVAST-M Clinical Trial) and C2195/A8466 (Predicting Relapse of Melanoma).
: P.G.C. reports personal fees from Novartis, MSD, BMS and Incyte, personal fees and grants from Celgene, outside the submitted work. M.R.M. reports personal fees from Amgen, grants and personal fees from Roche and GSK, grants from Astrazeneca, personal fees and other from Novartis, Rigontec and Array Biopharma, other from Astellas (was OSI) and Millenium, non-financial support and other from Immunocore, personal fees and other from BMS and Eisai, personal fees, non-financial support and other from Merck, personal fees from Cytomx, Bioline and Valo Therapeutics, other from Regeneron, Vertex, TCBiopharma, Pfizer and Replimune, outside the submitted work. P.L. reports personal fees and other from Agenus, Amgen, BMS, GSK, Lytix Biopharma, Merck, MSD, Nektar and Novartis, personal fees from NeraCare, grants, personal fees and other from Roche, outside the submitted work. The remaining authors declare no competing interests.